Rhumbline Advisers Sells 1,600 Shares of Chemed Corporation $CHE

Rhumbline Advisers reduced its stake in Chemed Corporation (NYSE:CHE) by 2.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 55,278 shares of the company’s stock after selling 1,600 shares during the quarter. Rhumbline Advisers owned about 0.38% of Chemed worth $26,916,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in CHE. Renasant Bank increased its position in Chemed by 2.3% during the first quarter. Renasant Bank now owns 815 shares of the company’s stock worth $501,000 after acquiring an additional 18 shares during the period. Cim LLC grew its position in shares of Chemed by 1.0% during the 1st quarter. Cim LLC now owns 2,029 shares of the company’s stock worth $1,248,000 after purchasing an additional 21 shares in the last quarter. Cynosure Group LLC increased its holdings in shares of Chemed by 4.3% during the first quarter. Cynosure Group LLC now owns 581 shares of the company’s stock worth $358,000 after purchasing an additional 24 shares during the period. Atria Investments Inc raised its position in shares of Chemed by 0.6% in the second quarter. Atria Investments Inc now owns 4,259 shares of the company’s stock valued at $2,074,000 after buying an additional 25 shares in the last quarter. Finally, Cetera Investment Advisers boosted its stake in shares of Chemed by 1.5% in the second quarter. Cetera Investment Advisers now owns 1,740 shares of the company’s stock valued at $847,000 after buying an additional 25 shares during the period. Institutional investors own 95.85% of the company’s stock.

Insiders Place Their Bets

In other news, Director Patrick P. Grace sold 150 shares of Chemed stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $463.39, for a total transaction of $69,508.50. Following the sale, the director directly owned 3,397 shares of the company’s stock, valued at approximately $1,574,135.83. This trade represents a 4.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $437.55, for a total value of $875,100.00. Following the completion of the transaction, the chief executive officer directly owned 94,197 shares of the company’s stock, valued at $41,215,897.35. This represents a 2.08% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,150 shares of company stock worth $2,328,449 in the last 90 days. 3.29% of the stock is currently owned by corporate insiders.

Chemed Trading Up 0.1%

CHE stock opened at $441.09 on Thursday. The firm has a 50-day moving average price of $441.15 and a 200-day moving average price of $475.74. Chemed Corporation has a 12 month low of $408.42 and a 12 month high of $623.60. The stock has a market capitalization of $6.25 billion, a P/E ratio of 23.33, a price-to-earnings-growth ratio of 2.69 and a beta of 0.43.

Chemed (NYSE:CHE) last released its quarterly earnings data on Tuesday, October 28th. The company reported $5.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). Chemed had a return on equity of 25.89% and a net margin of 11.02%.The company had revenue of $624.90 million for the quarter, compared to analyst estimates of $626.04 million. During the same quarter in the prior year, the company earned $5.64 earnings per share. Chemed’s revenue for the quarter was up 3.1% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities analysts predict that Chemed Corporation will post 21.43 EPS for the current fiscal year.

Chemed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Monday, November 17th will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Monday, November 17th. This represents a $2.40 annualized dividend and a dividend yield of 0.5%. Chemed’s dividend payout ratio (DPR) is 12.69%.

Analyst Ratings Changes

CHE has been the topic of several analyst reports. Bank of America reduced their target price on Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a report on Wednesday, September 10th. Oppenheimer reduced their price objective on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a research note on Thursday, July 31st. Weiss Ratings restated a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Finally, Jefferies Financial Group raised shares of Chemed from a “hold” rating to a “buy” rating and lifted their price objective for the company from $490.00 to $550.00 in a research note on Tuesday, September 2nd. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $574.25.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.